Skip to Content

PO BOX 683148 | Houston, TX 77268 | ph 888-247-8700 | fx 888-247-8706

NPTA is the largest professional society for pharmacy technicians. Membership is open to pharmacy technicians, students, and educators. more...

9-Oct-12 7:00 AM  CST  

Market Withdrawal of Teva’s 300mg Tablet of Generic Wellbutrin XL 

The Food and Drug Administration has asked for a voluntary market withdrawal of Teva Pharmaceuticals 300 mg tablet of generic Wellbutrin XL. As of right now, the 150 mg tablet of Budeprion XL is not included in the voluntary market withdrawal. The prescription medication is manufactured by Impax and marketed by Teva.    

The market withdrawal comes after complaints from consumers that their depression symptoms worsened, had suicidal thoughts, and also experienced headaches.   Here’s the science behind the problem with the drug.  Bioequivalence testing was never done on the drug and the drug approval was based on tests of the 150 mg tablet.  In addition, the Teva equivalent did not act as a once-a-day formula, but acted as an immediate release formula. 

According to a recent report on Web and the Generic Pharmaceutical Association (GPhA), more than 10,000 FDA approved generic drugs in the United States of 4 billion prescriptions in the U.S yearly, 80% are filled using generic drugs. 

Pharmacy technicians should be aware of this voluntary market withdrawal and inform their fellow pharmacy technicians of the drug news as questions may arise concerning the generic prescription medication and the release of this new information. 

Neporent, Liz.  “FDA Asks For Voluntary Recall Of Popular Antidepressant.”  ABC News.  Web.  4 Oct 2012. 

“Questions And Answerers Regarding Market Withdrawal Of Budeprion XL 300 mg Manufactured By Impax and Marketed By Teva.”  FDA.  Web.  5 Oct 2012.  

DeNoon, Daniel, J.  “High Dose Generic Wellbutrin XL Withdrawn.”  WebMD. Web.  5 Oct 2012.

  • Currently 3/5

Rating: 3.00 / 5.00  - Average
3 ratings

Add to Favorites


For additional information on this News article, please contact:

Jennifer O'Reilly

Source: NPTAnews

Related Documents:

Content Tags:

Tags: cpht FDA market withdrawal npta pharmacy technician wellbutrin


Other Recent Articles:

Return to Pharmacy Technician Articles Search

NPTA is lobbying for pharmacy technician issues, conducting industry-related research, developing benchmark reports, manage a national... more

NPTA is the #1 source for pharmacy technician products.


Are you Prepared? Chemotherapy Certification course